PI3K Inhibitors in B-Cell Lymphomas: A Summary Resource

Source: A Class in Session: Understanding Current and Future Therapeutic Advances Across B-Cell Lymphomas
Download PDF
Download this online resource developed to serve as a helpful guide for healthcare professionals on PI3K inhibitors in B-cell lymphoma.
Format: Adobe Acrobat (.pdf)
File Size: 336 KB
Released: December 13, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Atara Biotherapeutics, Inc.
Bayer HealthCare Pharmaceuticals Inc.
BeiGene, Ltd.
Epizyme
Genentech, a member of the Roche Group
Genmab US, Inc.
Incyte Corporation
Karyopharm Therapeutics
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings